Aggressive Non-Hodgkin Lymphoma — Trials

Aggressive Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

648 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 182
Recruiting: 92
Ph III recruiting: 4
Growth YoY: +6.7%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 51–100 of 648 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06927466	A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.	recruiting	Phase 1	33	Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.INDUSTRY	1	Aug 17, 2026	clinicaltrials
NCT07735533	A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies	not yet recruiting	Phase 1 / Phase 2	274	Umoja BiopharmaINDUSTRY	0	Aug 17, 2026